EFM
ORKA

E Fund Management’s Oruka Therapeutics ORKA Stock Holding History

E Fund Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$579K Buy
6,079
+989
+19% +$65.9K 0.01% 238
2026
Q1 		$250K Buy
+5,090
New +$177K 0.01% 418

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

E Fund Management's ORKA Position: Q2 2026 in Review

E Fund Management increased its Oruka Therapeutics (ORKA) stake by 19% in Q2 2026, buying an estimated $65.9K and bringing the position to 6,079 shares worth $579K. The position accounts for 0.01% of the portfolio, ranked #238.

E Fund Management first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • E Fund Management held 6,079 shares of Oruka Therapeutics worth $579K as of Q2 2026.
  • E Fund Management bought 989 Oruka Therapeutics shares in Q2 2026, an estimated $65.9K.
  • Oruka Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #238 holding.
  • E Fund Management first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.